SCHEMBL1679607

SCHEMBL1679607

CNC(=O)C1CCCCCC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 1/20 0.61
HDAC6 Q9UBN7 1/20 0.61
EPHX1 P07099 1/20 0.50
CES2 O00748 1/20 0.50
CES1 P23141 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.48
HSD17B10 Q99714 1/20 0.48
NAAA Q02083 1/20 0.47
TSHR P16473 2/20 0.47
MAPK1 P28482 1/20 0.47
HSD11B1 P28845 1/20 0.45
MAPT P10636 1/20 0.45
HTT P42858 1/20 0.45
PTPN1 P18031 1/20 0.45
HPGD P15428 1/20 0.45
CHRNB2 P17787 2/20 0.45
CHRNA4 P43681 2/20 0.45
CHRNA7 P36544 1/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL413228 1.00 HDAC8 (0.61) HDAC8HDAC6EPHX1CES2CES1
SCHEMBL18938465 1.00 HDAC8 (0.61) HDAC8HDAC6EPHX1CES2CES1
SCHEMBL18934846 1.00 HDAC8 (0.61) HDAC8HDAC6EPHX1CES2CES1
SCHEMBL13060381 1.00 HDAC8 (0.61) HDAC8HDAC6EPHX1CES2CES1
SCHEMBL6917808 1.00 HDAC8 (0.61) HDAC8HDAC6EPHX1CES2CES1
SCHEMBL24618011 1.00 HDAC8 (0.61) HDAC8HDAC6EPHX1CES2CES1
SCHEMBL1678569 1.00 HDAC8 (0.61) HDAC8HDAC6EPHX1CES2CES1
SCHEMBL18935496 1.00 HDAC8 (0.61) HDAC8HDAC6EPHX1CES2CES1
SCHEMBL21212072 1.00 HDAC8 (0.61) HDAC8HDAC6EPHX1CES2CES1
Hydrochloric Acid SCHEMBL7274485 0.97 HDAC8 (0.58) HDAC8HDAC6EPHX1CES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023196454-A1 ANTIVIRAL HETEROCYCLIC COMPOUNDS ENANTA PHARMACEUTICALS, INC. (US) 2023-10-12 WO disclosed
US-20230125803-A1 ANTIVIRAL HETEROCYCLIC COMPOUNDS ENANTA PHARM INC (US) 2023-04-27 US disclosed
WO-2021066922-A1 ANTIVIRAL HETEROCYCLIC COMPOUNDS ENANTA PHARMACEUTICALS, INC. (US) 2021-04-08 WO disclosed
US-10806791-B2 Carbohydrate conjugates as delivery agents for oligonucleotides ALNYLAM PHARMACEUTICALS, INC. (US) 2020-10-20 US disclosed
US-20190184018-A1 CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES BANK OF AMERICA, N.A. 2019-06-20 US disclosed
WO-2019111915-A1 ARTICLE DAIKIN AMERICA, INC. (US) 2019-06-13 WO disclosed
EP-2855435-B1 DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES PARION SCIENCES INC (US) 2018-04-11 EP disclosed
US-20170304459-A1 METHODS AND COMPOSITIONS FOR INHALATION DELIVERY OF CONJUGATED OLIGONUCLEOTIDE ALNYLAM PHARMACEUTICALS, INC. 2017-10-26 US disclosed
US-20170218151-A1 TRANSFER SHEET AND PROCESS FOR PRODUCING SAME DAIKIN INDUSTRIES, LTD. (JP) 2017-08-03 US disclosed
US-9556187-B2 Substituted pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidines and JAK inhibitors comprising the same NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2017-01-31 US disclosed
EP-1329160-A2 4-ACYLAMINOPYRAZOLE DERIVATIVES Sankyo Company, Limited (JP) 2003-07-23 EP disclosed
WO-2003033495-A1 QUINUCLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS M2 AND/OR M3 MUSCARINIC RECEPTOR INHIBITORS UCB, S.A. (BE) 2003-04-24 WO disclosed
US-5864043-A CARDIOVASCULAR DISORDERS AND ANGIOTENSIN ANTAGONIST KARL THOMAE GMBH (DE) 1999-01-26 US disclosed
US-5827863-A Pyrazole derivatives as angiotensin II antagonists J. URIACH & CIA, S.A. (ES) 1998-10-27 US disclosed
US-5614519-A (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists KARL THOMAE GMBH (DE) 1997-03-25 US disclosed
US-5602127-A ADMINISTERING TO TREAT HYPERTENSION KARL THOMAE GMBH (DE) 1997-02-11 US disclosed
US-5594003-A HYPOTENSIVE AGENTS DR. KARL THOMAE GMBH (DE) 1997-01-14 US disclosed
US-5591762-A HYPOTENSIVE AGENTS DR. KARL THOMAE GMBH (DE) 1997-01-07 US disclosed
US-5541229-A ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS DR. KARL THOMAE GMBH (DE) 1996-07-30 US disclosed
WO-1996004273-A1 NEW PYRAZOLE DERIVATIVES AS ANGIOTENSIN II ANTAGONIST J. URIACH & CIA, S.A. (ES) 1996-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190184018-A1 CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES SLC2A2, SLC2A8, SLC2A1 HDAC8 898/4885HDAC6 348/4885EPHX1 3944/4885
US-20170304459-A1 METHODS AND COMPOSITIONS FOR INHALATION DELIVERY OF CONJUGATED OLIGONUCLEOTIDE SLCO2B1, SLCO2A1, CHRM3 HDAC8 3452/4885HDAC6 1617/4885EPHX1 1582/4885
US-10806791-B2 Carbohydrate conjugates as delivery agents for oligonucleotides SLC2A2, SLC2A8, SLC2A1 HDAC8 898/4885HDAC6 348/4885EPHX1 3944/4885
US-20230125803-A1 ANTIVIRAL HETEROCYCLIC COMPOUNDS ACE, HPRT1, ACE2 HDAC8 1283/4885HDAC6 690/4885EPHX1 224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.